Ropeginterferon Alfa-2b vs Anagrelide in #ET: SURPASS-ET Study Results | EHA 2026

Dr. Lucia Masarova from MD Anderson Cancer Center presents data from the SURPASS-ET study, demonstrating the efficacy and safety of ropeginterferon alfa-2b compared to anagrelide in patients with essential thrombocythemia (ET).

STUDY OVERVIEW:
Second-line randomized study comparing ropeginterferon alfa-2b (novel injectable interferon) to anagrelide (standard oral therapy) in high-risk ET patients who previously received hydroxyurea.

KEY FINDINGS - ORIGINAL STUDY:
Ropeginterferon showed superior disease control with better platelet and white blood cell count management and improved symptom control.

KEY FINDINGS - CROSSOVER ANALYSIS:
Patients switched from anagrelide to ropeginterferon achieved 30% modified response within 3 months, with disease control improving in more than double the patients compared to anagrelide alone.

SAFETY PROFILE:
Ropeginterferon demonstrates similar or superior safety profile with no new safety concerns identified.

Learn more: https://linktr.ee/HealthTreeUniversity

TIMESTAMPS:
0:00 Introduction & MD Anderson Context
0:17 SURPASS-ET Study Overview
0:25 Drug Comparison: Ropeginterferon vs Anagrelide
0:33 Original Study Results & Approval
0:50 Disease Control Superiority
0:58 Crossover Analysis Details
1:13 3-Month Crossover Response Rates
1:28 Response Criteria & Patient Benefits
1:52 Safety Data & Preliminary Analysis
2:07 Comparative Safety Profile
2:17 Conclusion: Efficacy & Safety Advantages

#ET #EssentialThrombocythemia #Ropeginterferon #MPN #ClinicalTrial